JP2018501322A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501322A5 JP2018501322A5 JP2017555445A JP2017555445A JP2018501322A5 JP 2018501322 A5 JP2018501322 A5 JP 2018501322A5 JP 2017555445 A JP2017555445 A JP 2017555445A JP 2017555445 A JP2017555445 A JP 2017555445A JP 2018501322 A5 JP2018501322 A5 JP 2018501322A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- standard
- immune response
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 32
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 150000002632 lipids Chemical class 0.000 claims 12
- 108010034143 Inflammasomes Proteins 0.000 claims 10
- 230000028993 immune response Effects 0.000 claims 9
- 230000002163 immunogen Effects 0.000 claims 8
- 230000003213 activating effect Effects 0.000 claims 6
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000028709 inflammatory response Effects 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 241000224489 Amoeba Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000194033 Enterococcus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 101000735376 Homo sapiens Protocadherin-8 Proteins 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims 1
- PEZXEQJZQAVYCZ-NLMPBQEBSA-N PKODiA-PC Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCC(=O)\C=C\C(O)=O PEZXEQJZQAVYCZ-NLMPBQEBSA-N 0.000 claims 1
- 102100034958 Protocadherin-8 Human genes 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000028996 humoral immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020213211A JP7410846B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2020213210A JP7410845B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562102245P | 2015-01-12 | 2015-01-12 | |
| US62/102,245 | 2015-01-12 | ||
| PCT/US2016/012994 WO2016115097A2 (en) | 2015-01-12 | 2016-01-12 | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213211A Division JP7410846B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2020213210A Division JP7410845B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018501322A JP2018501322A (ja) | 2018-01-18 |
| JP2018501322A5 true JP2018501322A5 (enExample) | 2019-02-28 |
Family
ID=56406560
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555445A Pending JP2018501322A (ja) | 2015-01-12 | 2016-01-12 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2020213210A Active JP7410845B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2020213211A Active JP7410846B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2023015026A Active JP7719815B2 (ja) | 2015-01-12 | 2023-02-03 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2023015047A Active JP7719816B2 (ja) | 2015-01-12 | 2023-02-03 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2025041934A Pending JP2025090801A (ja) | 2015-01-12 | 2025-03-14 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2025041931A Pending JP2025094038A (ja) | 2015-01-12 | 2025-03-14 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213210A Active JP7410845B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2020213211A Active JP7410846B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2023015026A Active JP7719815B2 (ja) | 2015-01-12 | 2023-02-03 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2023015047A Active JP7719816B2 (ja) | 2015-01-12 | 2023-02-03 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2025041934A Pending JP2025090801A (ja) | 2015-01-12 | 2025-03-14 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2025041931A Pending JP2025094038A (ja) | 2015-01-12 | 2025-03-14 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US20180318414A1 (enExample) |
| EP (2) | EP3244923B1 (enExample) |
| JP (7) | JP2018501322A (enExample) |
| AU (2) | AU2021200638B2 (enExample) |
| CA (1) | CA2973585A1 (enExample) |
| ES (1) | ES3057334T3 (enExample) |
| WO (1) | WO2016115097A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2973585A1 (en) * | 2015-01-12 | 2016-07-21 | Children's Medical Center Corporation | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists |
| AU2017356295A1 (en) * | 2016-11-14 | 2019-05-23 | Beth Israel Deaconess Medical Center | Compositions and methods of treating cancer |
| EP3946456A4 (en) * | 2019-03-29 | 2023-05-03 | The Brigham and Women's Hospital, Inc. | TARGETED SYNERGISTIC CANCER IMMUNOTHERAPY |
| MX2022004186A (es) * | 2019-10-07 | 2022-07-19 | Northwest Biotherapeutics Inc | Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1. |
| EP4061423A4 (en) * | 2019-11-18 | 2023-12-06 | Children's Medical Center Corporation | HYPERACTIVE DENDRITIC CELLS FOR PERMANENT ANTITUMOR EFFECT ON ADOPTIONAL CELL TRANSFER BASIS |
| US20230076515A1 (en) * | 2019-11-18 | 2023-03-09 | Children's Medical Center Corporation | Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy |
| CN114894910B (zh) * | 2022-03-18 | 2023-10-20 | 重庆医科大学附属第一医院 | 1-棕榈酰-2-花生四烯酰-sn-甘油-3-磷酸胆碱检测试剂的新用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5158939A (en) * | 1989-07-21 | 1992-10-27 | Wisconsin Alumni Research Foundation | Method of stimulating the immune systems of animals and compositions useful therefor |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| PT1127137E (pt) * | 1998-11-03 | 2007-12-28 | Staat Nl Verteg Door Min Welzi | Lps com toxicidade reduzida a partir de bactérias gramnegativas modificadas geneticamente |
| WO2004006910A1 (de) * | 2002-07-15 | 2004-01-22 | Norbert Leitinger | Lipidoxidationsprodukte zur hemmung von entzündungen |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| US8961982B2 (en) * | 2005-12-16 | 2015-02-24 | The Regents Of The University Of California | Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer |
| CA2702340C (en) * | 2006-10-12 | 2014-12-16 | The University Of Queensland | Compositions and methods for modulating immune responses |
| WO2011013682A1 (ja) | 2009-07-27 | 2011-02-03 | 株式会社神戸製鋼所 | 配線構造およびその製造方法、並びに配線構造を備えた表示装置 |
| US20130108661A1 (en) | 2010-02-05 | 2013-05-02 | Mount Sinai School Of Medicine | Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells |
| CA2798074A1 (en) | 2010-04-27 | 2011-11-03 | The Johns Hopkins University | Immunogenic compositions and methods for treating neoplasia |
| CA2840170A1 (en) | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| EP2791101B1 (en) * | 2011-12-12 | 2019-09-18 | Vascular Biogenics Ltd. | Treatment of non-alcoholic steatohepatitis |
| WO2014164699A1 (en) | 2013-03-11 | 2014-10-09 | The Regents Of The University Of California | Herpes virus vaccines and treatments |
| EP3083945B1 (en) | 2013-12-18 | 2020-03-18 | Julius-Maximilians-Universität Würzburg | Galactose oxidase treatment of dendritic cells to improve their immunogenicity |
| CA2973585A1 (en) * | 2015-01-12 | 2016-07-21 | Children's Medical Center Corporation | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists |
| PT3291821T (pt) | 2015-05-07 | 2026-03-18 | Baylor College Medicine | Imunoterapêutica com células dendríticas |
| CN117244049A (zh) | 2016-02-16 | 2023-12-19 | 哈佛学院院长等 | 病原体疫苗及其生产和使用方法 |
| US11266746B2 (en) | 2016-06-27 | 2022-03-08 | The United Slates of America, as represented by the Secretary, Department of Health and Human Services | Therapeutic antitumor combination of a TLR4 ligand with other treatments |
| WO2018067302A2 (en) | 2016-09-19 | 2018-04-12 | North Western University | Therapeutic effects of cellular delivery of small molecules and macromolecules with liposomal spherical nucleic acids |
| JP7355394B2 (ja) | 2018-05-03 | 2023-10-03 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | カロテノイド組成物およびその使用 |
| MX2022004186A (es) | 2019-10-07 | 2022-07-19 | Northwest Biotherapeutics Inc | Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1. |
| US20230076515A1 (en) | 2019-11-18 | 2023-03-09 | Children's Medical Center Corporation | Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy |
| EP4061423A4 (en) | 2019-11-18 | 2023-12-06 | Children's Medical Center Corporation | HYPERACTIVE DENDRITIC CELLS FOR PERMANENT ANTITUMOR EFFECT ON ADOPTIONAL CELL TRANSFER BASIS |
-
2016
- 2016-01-12 CA CA2973585A patent/CA2973585A1/en active Pending
- 2016-01-12 EP EP16737709.2A patent/EP3244923B1/en active Active
- 2016-01-12 US US15/543,165 patent/US20180318414A1/en not_active Abandoned
- 2016-01-12 EP EP25205526.4A patent/EP4681782A3/en active Pending
- 2016-01-12 ES ES16737709T patent/ES3057334T3/es active Active
- 2016-01-12 JP JP2017555445A patent/JP2018501322A/ja active Pending
- 2016-01-12 WO PCT/US2016/012994 patent/WO2016115097A2/en not_active Ceased
-
2020
- 2020-09-11 US US17/018,038 patent/US11400153B2/en active Active
- 2020-09-11 US US17/018,045 patent/US11351250B2/en active Active
- 2020-12-23 JP JP2020213210A patent/JP7410845B2/ja active Active
- 2020-12-23 JP JP2020213211A patent/JP7410846B2/ja active Active
-
2021
- 2021-02-01 AU AU2021200638A patent/AU2021200638B2/en active Active
-
2022
- 2022-04-26 US US17/730,030 patent/US12070499B2/en active Active
- 2022-05-09 US US17/739,953 patent/US12053522B2/en active Active
-
2023
- 2023-02-03 JP JP2023015026A patent/JP7719815B2/ja active Active
- 2023-02-03 JP JP2023015047A patent/JP7719816B2/ja active Active
-
2024
- 2024-06-18 US US18/746,749 patent/US20240415957A1/en active Pending
- 2024-07-17 US US18/774,985 patent/US20250025552A1/en active Pending
- 2024-09-06 AU AU2024219454A patent/AU2024219454A1/en active Pending
-
2025
- 2025-03-14 JP JP2025041934A patent/JP2025090801A/ja active Pending
- 2025-03-14 JP JP2025041931A patent/JP2025094038A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shah et al. | Overview of vaccine adjuvants: introduction, history, and current status | |
| US20230116042A1 (en) | Adjuvant formulations comprising tlr4 agonists and methods of using the same | |
| Silva et al. | Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses | |
| Mori et al. | The vaccine adjuvant alum inhibits IL‐12 by promoting PI 3 kinase signaling while chitosan does not inhibit IL‐12 and enhances T h1 and T h17 responses | |
| CN106163551B (zh) | 单瓶疫苗制剂 | |
| Plaisance et al. | Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections | |
| Khademi et al. | Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost? | |
| HRP20150177T1 (hr) | Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva | |
| Bramwell et al. | The rational design of vaccines | |
| HRP20160816T1 (hr) | Upotreba virusa influence i emulzije ulja u vodi kao adjuvansa radi poticanja t-stanica cd4 i/ili poboljšanog odgovora memorijskih b-stanica | |
| JP6403738B2 (ja) | デンプンを使用する経口ワクチン速溶性剤型 | |
| Todoroff et al. | Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery | |
| EP1618889A3 (en) | Influenza Vaccine | |
| RU2013114980A (ru) | Вакцинная композиция | |
| JP2010523711A5 (enExample) | ||
| Kianmehr et al. | Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice | |
| Mbawuike et al. | Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant | |
| RU2010129770A (ru) | Вакцина против гриппа и способ ее получения | |
| RU2016141621A (ru) | Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин | |
| JP2018532742A5 (enExample) | ||
| EP4421174A3 (en) | Adjuvant comprising a glycoarchaeol and an immunostimulant | |
| JP2008539169A5 (enExample) | ||
| WO2006114680A3 (en) | Vaccine adjuvants | |
| CO6511241A2 (es) | Régimen de inmunizaión por sensibilización-refuerzo heteróloga | |
| RU2010111766A (ru) | Способы усиления адъювантного действия композиций вакцин |